Timmy Davis - Identifying and mitigating barriers to accessing psychedelic medicines

Timmy Davis argues for overcoming systemic hurdles to the equitable and realistic clinical integration of psychedelic medicines. He highlights the dangers of a narrow, high-cost medical model which could create significant barriers to access and exclude vulnerable patient populations. Davis proposes decentralizing care to empower qualified practitioners outside of hospital settings while ensuring accountability through standardized training registries and data collection frameworks. Case studies on medical cannabis and ketamine provide examples of current challenges, warning that without preemptive policy reform, the transition to legal psychedelic treatments risks becoming an exclusionary medical monoculture.